LIMOGES, France--(BUSINESS WIRE)--Regulatory News:
Total number of shares
|Total number of voting rights|
|August 31, 2017||266,750,200||
Theoretical number of voting rights:
Number of exercisable voting rights*:
(*) After deduction of shares without voting rights
The variation of the total number of shares since the latest release of financial statements is reminded below:
|Total number of shares as at June 30, 2017||266,598,466|
|Exercise of stock options||15,815|
|Total number of shares as at July 31, 2017||266,614,281|
|Exercise of stock options||135,919|
|Total number of shares as at August 31, 2017||266,750,200|
* * *
Key financial dates:
2017 nine-month results: November 7, 2017
“Quiet period1” starts October 7, 2017
2017 annual results: February 8, 2018
“Quiet period1” starts January 9, 2018
- General Meeting of Shareholders: May 30, 2018
Legrand is the global specialist in electrical and digital building
infrastructures. Its comprehensive offering of solutions for commercial,
industrial and residential markets makes it a benchmark for customers
worldwide. Drawing on an approach that involves all teams and
stakeholders, Legrand is pursuing its strategy of profitable and
sustainable growth driven by acquisitions and innovation, with a steady
flow of new offerings—including Eliot* connected products with enhanced
value in use. Legrand reported sales of more than €5 billion in 2016.
The company is listed on Euronext Paris and is a component stock of
indexes including the CAC 40, FTSE4Good, MSCI World, Corporate Oekom
Rating, DJSI World, Vigeo Euronext Eurozone 120, Europe 120 and France
20, and Ethibel Sustainability Index Excellence.
(code ISIN FR0010307819).
*Eliot is a program launched in 2015 by Legrand to speed up
deployment of the Internet of Things in its offering. A result of the
group’s innovation strategy, Eliot aims to develop connected and
interoperable solutions that deliver lasting benefits to private
individual users and professionals.
1 Period of time when all communication is suspended in the run-up to publication of results.